Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Laura Hailstone, David Tovmassian, Chu Luan Nguyen, Pearl Wong, Philip Alexander Le Page, David Martin, Craig Taylor
PURPOSE: This study presents the short- (less than 6 months) and medium-term (6 months to 2 years) outcomes for weight loss and type 2 diabetes mellitus (T2DM) for all patients undergoing one anastomosis gastric bypass (OAGB) across multiple institutions between 2015 and 2021. MATERIALS AND METHODS: A retrospective analysis of prospectively collected databases was performed including 1022 participants who underwent OAGB at multiple institutions by multiple surgeons between 2015 and 2021...
April 12, 2024: Obesity Surgery
#2
RANDOMIZED CONTROLLED TRIAL
Matthias Lannoo, Caroline Simoens, Roman Vangoitsenhoven, Pieter Gillard, André D'Hoore, Mieke De Vadder, Ann Mertens, Ellen Deleus, Nele Steenackers, Chantal Mathieu, Bart Van der Schueren
Although bariatric surgery is an effective treatment for type 2 diabetes by inducing weight loss and augmenting gut hormone secretion, the immediate effect on beta-cell function itself remains to be elucidated in type 2 diabetes. Therefore, a prospective, randomized trial was performed in 30 patients with insulin-treated type 2 diabetes and a body mass index ≥ 35 kg/m2 . Patients were randomly assigned (1:1:1) to Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) in combination with protein-sparing modified fast (PSMF), or to PSMF alone...
April 8, 2024: Scientific Reports
#3
JOURNAL ARTICLE
Shelby Remmel, Madison Noom, Reagan Sandstrom, Rahul Mhaskar, Abdul-Rahman Fadi Diab, Joseph Adam Sujka, Salvatore Docimo, Christopher Garnet DuCoin
INTRODUCTION: The purpose of this study is to investigate the impact of preoperative comorbidities, including depression, anxiety, type 2 diabetes mellitus, obstructive sleep apnea, hypothyroidism, and the type of surgery on %EBWL (percent estimated body weight loss) in patients 1 year after bariatric surgery. Patients who choose to undergo bariatric surgery often have other comorbidities that can affect both the outcomes of their procedures and the postoperative period. We predict that patients who have depression, anxiety, diabetes mellitus, obstructive sleep apnea, or hypothyroidism will have a smaller change in %EBWL when compared to patients without any of these comorbidities...
April 5, 2024: Surgical Endoscopy
#4
JOURNAL ARTICLE
Süleyman Baldane, Murat Celik, Muslu Kazim Korez, Huseyin Yilmaz, Sedat Abusoglu, Levent Kebapcilar, Husnu Alptekin
INTRODUCTION: Our study aimed to compare the short- and particularly long-term type 2 diabetes mellitus (T2DM) remission prediction abilities of ABCD, individualised metabolic surgery (IMS), DiaRem2, Ad-DiaRem and DiaBetter scoring systems in Turkish adult type 2 diabetic morbidly obese patients who underwent bariatric surgery. PATIENTS AND METHODS: Our study was planned as a retrospective cohort study. A total of 137 patients with T2DM, including 78 sleeve gastrectomy (SG) and 59 Roux-en-Y gastric bypass (RYGB) patients, were included in the 1st-year evaluation after bariatric surgery, and a total of 115 patients with T2DM, including 64 SG and 51 RYGB patients, were included in the evaluation at the end of the 5th year...
March 28, 2024: Journal of Minimal Access Surgery
#5
JOURNAL ARTICLE
Pietra S Rodrigues, Fernando M Mendonça, João S Neves, Carla Luís, Ilda Rodrigues, Telma Moreno, Diana Festas, Jorge Pedro, Ana Varela, Ana Fernandes, Eduardo L Costa, Paula Freitas
INTRODUCTION: Sarcopenic obesity (SO) is characterised by the confluence of muscle deterioration and high adiposity. When non-surgical interventions prove insufficient, bariatric surgery (BS) becomes the primary approach. This study aimed to address BS effects on SO outcomes 1 year post-surgery among middle-aged women, also considering physical exercise's impact. METHODS: Prospective single-centre study of 140 patients who underwent Roux-en-Y gastric bypass or sleeve gastrectomy between November 2019 and December 2022...
March 25, 2024: Obesity Surgery
#6
RANDOMIZED CONTROLLED TRIAL
Maud Robert, Tigran Poghosyan, Delphine Maucort-Boulch, Alexandre Filippello, Robert Caiazzo, Adrien Sterkers, Lita Khamphommala, Fabian Reche, Vincent Malherbe, Adriana Torcivia, Toufic Saber, Dominique Delaunay, Carole Langlois-Jacques, Augustin Suffisseau, Sylvie Bin, Emmanuel Disse, François Pattou
BACKGROUND: The multicentre randomised trial YOMEGA (NCT02139813) comparing the one anastomosis gastric bypass (OAGB) with the Roux-en-Y gastric bypass (RYGB) confirmed the non-inferiority of OAGB on weight loss outcomes at 24 months. We aimed to report weight loss, metabolic, and safety outcomes at 5 years. METHODS: YOMEGA is a prospective, open-label, non-inferiority, randomised trial conducted at nine centres in France. Inclusion criteria were BMI of 40 kg/m2 or more, or 35 kg/m2 or more with comorbidities...
April 2024: Lancet Diabetes & Endocrinology
#7
JOURNAL ARTICLE
Jan Kral, Marek Benes, Vera Lanska, Peter Macinga, Pavel Drastich, Julius Spicak, Tomas Hucl
PURPOSE: Obesity and its related severe comorbidities are increasing rapidly. The duodenal-jejunal bypass is an endoscopically implanted device (mimicking the Roux-en-Y gastric bypass) developed to support weight reduction and improve type 2 diabetes control. MATERIALS AND METHODS: Retrospective data analysis of consecutive patients undergoing duodenal-jejunal bypass (EndoBarrier®, DJB) implantation between 2013 and 2017 was performed to evaluate safety as well as short- and long-term efficacy...
December 19, 2023: Obesity Surgery
#8
REVIEW
Jonah A Hoyt, Emily Cozzi, David A D'Alessio, Chris C Thompson, Vanita R Aroda
Affecting 5%-10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long-term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. However, fewer than half of those living with T2DM reach their glycaemic targets despite the availability of multiple oral and injectable medications. Adherence and access to medications are major barriers contributing to suboptimal diabetes treatment...
March 4, 2024: Diabetes, Obesity & Metabolism
#9
JOURNAL ARTICLE
Hang Yu, Lulu Qian, Yu Yan, Qi Yang, Xiaodong Shan, Youwei Chen, Xiao Fu, Xuehui Chu, Xing Kang, Xitai Sun
The objective of this study was to evaluate and compare the effectiveness of three different types of bariatric surgeries, namely, sleeve gastrectomy (SG), one-anastomotic gastric bypass (OAGB), and single anastomosis sleeve ileal (SASI) bypass, in the treatment of metabolic syndrome (MS). The optimal approach for managing MS remains uncertain, and thus this study aimed to provide a recent analysis of the efficacy of these surgical procedures. This retrospective study evaluated data of individuals who underwent SG, OAGB, and SASI bypass...
March 1, 2024: Scientific Reports
#10
REVIEW
Katarzyna Smolarczyk, Blazej Meczekalski, Ewa Rudnicka, Katarzyna Suchta, Anna Szeliga
Obesity and obesity-related conditions today constitute a public health problem worldwide. Obesity is an "epidemic" chronic disorder, which is defined by the WHO as normal or excessive fat accumulation that may impair health. It is also defined for adults as a BMI that is greater than or equal to 30. The most common obesity-related diseases are type 2 diabetes mellitus, cardiovascular diseases, metabolic syndrome, chronic kidney disease, hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and certain types of cancer...
February 14, 2024: Medicina
#11
REVIEW
Mohamed Elsaigh, Bakhtawar Awan, Ahmed Shabana, Azka Sohail, Ahmad Asqalan, Omnia Saleh, Justyna Szul, Rana Khalil, Hatem Elgohary, Mohamed Marzouk, Mohamed Alasmar
Sleeve Gastrectomy (SG) could be done by the removal of a big portion of the stomach, leading to reduced amounts of food taken as a result of the smaller stomach size. In contrast, Roux-en-Y Gastric Bypass (RYGB) can be done by creating a small stomach pouch and rerouting a part of the small intestine, employing combined mechanisms of restriction and malabsorption to limit food intake and modify nutrient absorption. Our aim is to identify the most effective and safest surgical intervention for individuals with both Type 2 Diabetes Mellitus (T2DM) and obesity, considering both short and long-term outcomes...
January 2024: Curēus
#12
JOURNAL ARTICLE
Hala Khalf Allah El-Shreef, Osama Yaseen Mostafa Taha, Heba Ahmed Abd El Hafeez, Amal Ibrahim Abd El-Rheem Abo Shoka
BACKGROUND AND GOAL: The pandemic of the twenty-first century is diabetes. Both type 2 diabetes mellitus and obesity pose severe problems for public health. Despite significant improvements in diagnosing and managing both conditions, diabetes mellitus remains poorly controlled, and diabetic complications are more common than ever. Internists have discovered over the past 20 years that obese people with type 2 diabetes who have gastric bypass surgery to shed weight have improved glycemic control...
February 19, 2024: Diabetology & Metabolic Syndrome
#13
REVIEW
Willian Ferreira Igi, Victor Lira de Oliveira, Ayah Matar, Diogo Turiani Hourneaux de Moura
The treatment of obesity and its comorbidities ranges from clinical management involving lifestyle changes and medications to bariatric and metabolic surgery. Various endoscopic bariatric and metabolic therapies (EBMT) recently emerged to address an important therapeutic gap by offering a less invasive alternative to surgery that is more effective than conservative therapies. This article comprehensively reviews the technical aspects, mechanism of action, outcomes, and future perspectives of one of the most promising EBMT, named duodenojejunal bypass liner (DJBL)...
February 15, 2024: Clinical Endoscopy
#14
JOURNAL ARTICLE
Omar M Ghanem, Kamal Abi Mosleh, Anthony Kerbage, Lauren Lu, Karl Hage, Barham K Abu Dayyeh
BACKGROUND: Roux-en-Y gastric bypass (RYGB) demonstrates high rates of type-2 diabetes mellitus (T2DM) remission, a phenomenon hypothesized to be mediated mainly by weight loss. Compared to procedures that do not bypass the proximal small-intestines, such as sleeve gastrectomy (SG), RYGB exhibits weight-loss independent intestinal mechanisms conducive to T2DM remission. We investigated continued diabetes remission (CDR) rates despite weight recurrence (WR) after RYGB compared to a SG cohort...
February 13, 2024: Journal of the American College of Surgeons
#15
JOURNAL ARTICLE
Karl Hage, Kamal Abi Mosleh, Jack W Sample, Robert A Vierkant, Manpreet S Mundi, Konstantinos Spaniolas, Barham K Abu Dayyeh, Omar M Ghanem
BACKGROUND: Roux-en-Y gastric bypass (RYGB) has demonstrated excellent glycemic control and type 2 diabetes mellitus (T2DM) remission for patients with obesity and T2DM. Duration of T2DM is a consistent negative predictor of remission after RYGB. However, the exact timing to offer surgical intervention during the course of the disease is not well elucidated. MATERIAL AND METHODS: We performed a retrospective cohort study between 2008-2020 to establish the exact association between duration of T2DM and remission after RYGB...
February 9, 2024: International Journal of Surgery
#16
JOURNAL ARTICLE
Mohammad Kermansaravi, Sonja Chiappetta, Chetan Parmar, Scott A Shikora, Gerhard Prager, Teresa LaMasters, Jaime Ponce, Lilian Kow, Abdelrahman Nimeri, Shanu N Kothari, Edo Aarts, Syed Imran Abbas, Ahmad Aly, Ali Aminian, Ahmad Bashir, Estuardo Behrens, Helmuth Billy, Miguel A Carbajo, Benjamin Clapp, Jean-Marc Chevallier, Ricardo V Cohen, Jerome Dargent, Bruno Dillemans, Silvia L Faria, Manoel Galvao Neto, Pierre Y Garneau, Khaled Gawdat, Ashraf Haddad, Mohamad Hayssam ElFawal, Kelvin Higa, Jaques Himpens, Farah Husain, Matthew M Hutter, Kazunori Kasama, Radwan Kassir, Amir Khan, Mousa Khoursheed, Matthew Kroh, Marina S Kurian, Wei-Jei Lee, Ken Loi, Kamal Mahawar, Corrigan L McBride, Hazem Almomani, John Melissas, Karl Miller, Monali Misra, Mario Musella, C Joe Northup, Mary O'Kane, Pavlos K Papasavas, Mariano Palermo, Richard M Peterson, Ralph Peterli, Luis Poggi, Janey S A Pratt, Aayad Alqahtani, Almino C Ramos, Karl Rheinwalt, Rui Ribeiro, Ann M Rogers, Bassem Safadi, Paulina Salminen, Sergio Santoro, Nathaniel Sann, John D Scott, Asim Shabbir, Stephanie Sogg, Erik Stenberg, Michel Suter, Antonio Torres, Surendra Ugale, Ramon Vilallonga, Cunchuan Wang, Rudolf Weiner, Natan Zundel, Luigi Angrisani, Maurizio De Luca
Metabolic and bariatric surgery (MBS) is widely considered the most effective option for treating obesity, a chronic, relapsing, and progressive disease. Recently, the American Society of Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) issued new guidelines on the indications for MBS, which have superseded the previous 1991 National Institutes of Health guidelines. The aim of this study is to establish the first set of consensus guidelines for selecting procedures in Class I and II obesity, using an Expert Modified Delphi Method...
February 11, 2024: Scientific Reports
#17
JOURNAL ARTICLE
Claudio Gambardella, Federico Maria Mongardini, Maddalena Paolicelli, Francesco Saverio Lucido, Salvatore Tolone, Luigi Brusciano, Simona Parisi, Rosetta Esposito, Francesco Iovino, Luca Nazzaro, Francesco Pizza, Ludovico Docimo
Background. Obesity is a prevalent condition associated with various comorbidities, impacting mortality, fertility, and quality of life. Its relationship with type 2 diabetes mellitus (DMII) is well established, with nearly 44% prevalence. Bariatric surgery has proven crucial for treating both obesity and DMII. The comparison between surgical techniques, such as sleeve gastrectomy (SG) and one anastomosis gastric bypass (OAGB), remains controversial in terms of glycemic control efficacy. This retrospective study aimed to assess DMII remission efficacy between SG and OAGB after 36 months...
February 4, 2024: Journal of Clinical Medicine
#18
JOURNAL ARTICLE
Anne-Sophie van Rijswijk, Abraham S Meijnikman, Sarah Mikdad, Barbara A Hutten, Donald L van der Peet, Arnold W van de Laar, Victor E A Gerdes, Maurits de Brauw
BACKGROUND: Glycemic control is an important goal of bariatric surgery in patients with type 2 diabetes mellitus (T2DM) and obesity. The laparoscopic one-anastomosis gastric bypass (OAGB) has potential metabolic benefits over the laparoscopic Roux-en-Y gastric bypass (RYGB). Aim of this study is to examine whether RYGB or OAGB grants better glycemic control 12 months post-surgery. METHODS: For this retrospective cohort study, patients with T2DM and obesity, who underwent primary OAGB between 2008 and 2017 were reviewed...
February 6, 2024: Obesity Surgery
#19
JOURNAL ARTICLE
Wissam Ghusn, Marita Salame, Lea Sayegh, Karl Hage, Andrew C Storm, Barham K Abu Dayyeh, Omar M Ghanem
BACKGROUND: Type-2 diabetes mellitus (T2DM) results in detrimental vascular complications including both microvascular and macrovascular diseases. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are effective weight-loss therapies that enhance T2DM remission. However, limited data are present regarding the association between diabetes-associated diseases before RYGB and SG with T2DM remission. METHODS: This is a retrospective cohort study in patients with T2DM who underwent RYGB or SG...
February 2, 2024: Surgical Endoscopy
#20
JOURNAL ARTICLE
Karl Hage, Pearl Ma, Wissam Ghusn, Kayla Ikemiya, Andres Acosta, Robert A Vierkant, Barham K Abu Dayyeh, Kelvin D Higa, Omar M Ghanem
OBJECTIVE: Multiple scores validate long-term type-2 diabetes mellitus (T2DM) remission after metabolic and bariatric surgery (MBS). However, studies comparing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have not adequately controlled for certain parameters, which may influence procedure selection. METHODS: We conducted a multicenter retrospective review of patients with T2DM who underwent RYGB or SG between 2008 and 2017. Data on demographics, clinical, laboratory, and metabolic values were collected annually for up to 14 years...
January 22, 2024: Surgical Innovation
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
